Zimbabwe has declined a major American healthcare agreement worth 367 million US dollars (272 million pounds) over five years over Washington's demand for confidential data.
This rejection came to light after a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official representative later explained that the US was seeking health data for research and profit but refused to guarantee the benefits from future medical innovations.
"We will now turn to the difficult and regrettable task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more negotiations to find a deal suitable to all parties so the country's vital HIV programme can proceed.
Wider Implications
This development comes after a similar case in neighbouring Kenya, where a court halted a related health funding agreement after legal challenges were raised about the security of Kenyans' health data.
Since resuming office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government agreements to boost transparency and accountability.
As per statements, 16 nations in Africa have so far signed these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data for a long time, with no equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that shared data," he stated.
"In essence, our nation would provide the basic resources for medical research with no certainty that the end products would be accessible to our people if a new pandemic arise."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its pursuit of bilateral deals were disrupting frameworks previously set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This mechanism is intended to ensure that when a country provides its data, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to create them."
The government's concerns over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further dialogue with our US partners on how subsequent collaboration could be arranged in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
Medical experts expressed it recognised the official position, but suggested that negotiations should continue considering much of the nation's HIV programmes relied on external financing.
"If technical issues arise, including those involving information security or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," it added.
This impasse highlights the complex challenges between accepting vital international aid and protecting local interests in an ever more data-driven world.